Core Insights - Ionis Pharmaceuticals and Sobi announced the approval of TRYNGOLZA (olezarsen) in the European Union for treating genetically confirmed familial chylomicronemia syndrome (FCS) as an adjunct to diet [1] - The approval was based on a positive opinion from the Committee for Medicinal Products for Human Use [1] - The decision follows positive data from the Phase 3 Balance study, where TRYNGOLZA 80 mg demonstrated efficacy [1]